ID   K562-IMR
AC   CVCL_D201
SY   K562-IM-R; K562 IMR; K562/IMR
DR   Wikidata; Q54899392
RX   PubMed=18829496;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 19
//
RX   PubMed=18829496; DOI=10.1158/1078-0432.CCR-08-0461;
RA   Okabe S., Tauchi T., Ohyashiki K.;
RT   "Characteristics of dasatinib- and imatinib-resistant chronic
RT   myelogenous leukemia cells.";
RL   Clin. Cancer Res. 14:6181-6186(2008).
//